Exploration into the lipid management and persistent risk in the patients hospitalized for acute coronary syndrome in Japa
Not Applicable
- Conditions
- Acute Coronary Syndrome (ACS)
- Registration Number
- JPRN-UMIN000018946
- Lead Sponsor
- Sanofi K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
1) ACS accompanied by or precipitated by significant comorbidity. 2) Enrolled other lipid interventional studies 3) Patients with sub-acute stent-thrombosis caused by revascularization procedures.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The persistent risk will be defined as the incidence of major adverse cardiovascular events (MACE)
- Secondary Outcome Measures
Name Time Method [1] Coronary revascularization based on myocardial ischemia#2 [2] Revascularization excluding the heart [3] Inpatient treatment due to occurrence or exacerbation of heart failure [4] Transient ischemic attack (TIA)#3 [5] Acute arterial obstruction [6] Central retinal artery occlusion [7] Other adverse events prolonging or requiring hospitalization